Open Label, Two Cohort (With and Without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients With Gaucher Disease Type 1 and Type 3
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Eliglustat (Primary) ; Imiglucerase (Primary)
- Indications Gaucher's disease type I; Gaucher's disease type III
- Focus Adverse reactions; Pharmacokinetics; Registrational
- Acronyms ELIKIDS
- Sponsors Sanofi; Sanofi Genzyme
- 28 Aug 2019 Planned End Date changed from 1 Mar 2023 to 1 Nov 2025.
- 13 Apr 2018 Status changed from not yet recruiting to recruiting.
- 04 Apr 2018 New trial record